Inhaled nitric oxide for people with moderate-to-severe chronic obstructive pulmonary disease
Tests inhaled nitric oxide for exercise tolerance and safety in people with COPD.
Plain-language title generated from the registry record
Registry title: A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Nanjing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT07382258, who can take part
Where in China
- The First Affiliated Hospital with Nanjing Medical UniversityNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novlead Inc.
- Trial code
- NCT07382258
- Record updated
- 2 February 2026
- Original description
This clinical trial aims to assess the impact on exercise tolerance and the safety of inhaled nitric oxide in subjects with moderate-to-severe COPD. The findings are expected to contribute to the development of safe and effective therapeutic strategies for COPD management.Read full original descriptionShow less
A Prospective, Single-Center Study of Inhaled Nitric Oxide in Individuals Diagnosed With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
This clinical trial aims to assess the impact on exercise tolerance and the safety of inhaled nitric oxide in subjects with moderate-to-severe COPD. The findings are expected to contribute to the development of safe and effective therapeutic strategies for COPD management.
Inclusion: Aged between 40 and 75 years, inclusive; History of smoking with a cumulative exposure of ≥10 pack-years, and having ceased smoking for at least one month prior to study participation; Diagnosis of moderate-to-severe COPD confirmed by post-bronchodilator spirometry: FEV1/FVC < 0.7 and FEV1 between 30% and 80% of predicted value; Willing and able to provide written informed consent and comply with all study-related procedures.
Exclusion: Experienced a COPD exacerbation within the past month requiring initiation or escalation of systemic corticosteroids; Significant valvular heart disease (moderate/severe aortic or mitral stenosis/regurgitation) or prior mitral valve replacement; Use of approved pulmonary hypertension medications (e.g., sildenafil, bosentan, prostacyclins) within 30 days prior to screening or during the study; Participation in another interventional clinical trial involving drugs or devices within 30 days prior to enrollment; Current diagnosis of asthma or any other active respiratory condition considered non-COPD by the investigator; Any other medical or psychiatric condition that, in the investigator's judgment, would compromise patient safety or study integrity; Impaired left ventricular systolic function, defined as left ventricular ejection fraction (LVEF) < 50%; Pregnancy or lactation; Use of nicotine-containing products (e.g., patches, gum) within the past month; Physical obstruction of the nasal passages.